Prevalence of high-risk human papillomavirus cervical infection in female kidney graft recipients: an observational study
© Pietrzak et al.; licensee BioMed Central Ltd. 2012
Received: 18 December 2011
Accepted: 31 May 2012
Published: 18 June 2012
Immunosuppressive therapy protects the transplanted organ but predisposes the recipient to chronic infections and malignancies. Transplant patients are at risk of cervical intraepithelial neoplasia (CIN) and cervical cancer resulting from an impaired immune response in the case of primary infection or of reactivation of a latent infection with human papillomavirus of high oncogenic potential (HR-HPV).
The aim of this study was to assess the prevalence of HR-HPV cervical infections and CIN in 60 female kidney graft recipients of reproductive age in comparison to that in healthy controls. Cervical swabs were analyzed for the presence of HR-HPV DNA. HR-HPV-positive women remained under strict observation and were re-examined after 24 months for the presence of transforming HR-HPV infection by testing for HR-HPV E6/E7 mRNA. All the HR-HPV-positive patients were scheduled for further diagnostic tests including exfoliative cytology, colposcopy and cervical biopsy.
The prevalence of HR-HPV did not differ significantly between the study group and the healthy controls (18% vs 25%, p = 0.37). There was no correlation between HR-HPV presence and the immunosuppresive regimen, underlying disease, graft function or time interval from transplantation. A higher prevalence of HR-HPV was observed in females who had had ≥2 sexual partners in the past. Among HR-HPV-positive patients, two cases of CIN2+ were diagnosed in each group. In the course of follow-up, transforming HR-HPV infections were detected in two kidney recipients and in one healthy female. Histologic examination confirmed another two cases of CIN2+ developing in the cervical canal.
Female kidney graft recipients of reproductive age are as exposed to HR-HPV infection as are healthy individuals. Tests detecting the presence of HR-HPV E6/E7 mRNA offer a novel diagnostic opportunity in those patients, especially in those cases where lesions have developed in the cervical canal.
KeywordsRenal transplantation HPV mRNA HR-HPV Immunosuppressive therapy Cervical intraepithelial neoplasia
Solid organ recipients receive immunosuppressive therapy to protect the transplanted organ against rejection, which therapy also unfortunately predisposes them to chronic infections and the development of malignancies . According to the literature data renal transplant recipients have a high risk of developing anogenital tract malignancies [2, 3]. Carcinoma of the uterine cervix accounts for approximately 3% of all malignancies among transplant patients . Renal transplantation increases the incidence of cervical intraepithelial neoplasia up to 14–16 fold, and that of invasive cervical cancer 3.0–8.6 fold [5–7]. The actual role of immunosuppressive therapy in the development of malignancy remains unclear. In the light of current data, it seems that immunosuppression, while not causing the progression of the carcinoma itself, is mostly linked to the early stages of dysplasia due to the mechanisms responsible for the elimination of high-risk human papillomavirus (HR-HPV) infection being defective . At present there are still no convincing and unanimous HPV screening data from renal transplant recipients. Positive HR-HPV DNA tests are more sensitive than exfoliative cytology in predicting females at risk of developing cervical intraepithelial neoplasia (CIN) or carcinoma of the cervix . However, HR-HPV DNA tests have poor diagnostic specificity. This is due to the very high prevalence of transient HPV infections , as opposed to the persistent HPV infections that lead to precancerous and cancerous lesions of the uterine cervix. This is characterized by a shift from a productive to a transforming infection resulting from a switch in viral gene expression. Increased expression of viral oncogenes E6 and E7 prevents the infected cells from terminal differentiation by interfering with cell-cycle regulating proteins p53 and Rb. This leads to the HPV infection being maintained, because infected cells do not undergo apoptosis, but on the contrary experience activation of their pro-proliferative genes [11, 12]. The specificity of cervical screening might therefore be improved by the detection of biomarkers distinctive of transforming infection. Obviously, HPV DNA testing alone cannot discriminate between transient and transforming infections. However, the expression of viral oncogenes E6 and E7 is regarded as a signal of potential progression to invasive cervical cancer . Therefore it was proposed that the detection of HPV E6 and E7 mRNAs could serve to identify patients with an elevated risk of CIN and cervical cancer . The study was designed to investigate the prevalence of HR-HPV DNA in cervical specimens, as well as the prevalence of transforming HPV infection among HPV-positive females, by detecting HPV E6 and E7 mRNAs. It also aimed to assess the clinical value of these tests in the cervical screening of kidney graft recipients in comparison to that of healthy women.
HR-HPV infection was diagnosed in 11/60 kidney graft recipients and 15/60 healthy women, indicating a comparable infection rate (p = 0.37) in the two groups. HR-HPV was detected significantly more often in females having had >2 sexual partners in the past. There was, however, no correlation observed between the presence of HPV in kidney graft recipients and serum creatinine concentration, age, body mass index (BMI), immunosuppressive therapy regimen and underlying or coexisting diseases.
On initial screening, among the HR-HPV DNA-positive women abnormal Pap smear results were detected in two kidney graft recipients (2 cases of HSIL) and two healthy women (LSIL and HSIL). After colposcopy-guided cervical biopsy, in all cases CIN2+ was diagnosed and the patients were scheduled for further treatment. Three of them were offered loop electrosurgical excision procedure (LEEP) and histological examination confirmed that the lesions were excised with negative margins. In one case (a transplant patient) extirpation of the uterus was offered because of concomitant uterine fibroids accompanied by excessive menstrual bleeding, leading to severe anemia that was resistant to hormonal therapy.
On follow-up after twenty four months, it was established that the rate of clearance of HR-HPV infection of the uterine cervix was similar in both groups, reaching 81,8% in the study group. In the control group, all women but one (93%) were HR-HPV negative at the time of follow-up (p = ns).
Among renal transplant recipients, a persistent infection with HR-HPV was confirmed in two cases. Both women had a positive E6/E7 mRNA test and were scheduled for additional investigations. After colposcopy-guided cervical biopsy, CIN3 was diagnosed in one case and the patient was scheduled for further treatment (LEEP excision procedure). The histological evaluation of specimens from the cervical canal confirmed the previous diagnosis of CIN3. Significantly, this patient displayed a normal cervical cytology, even though the pathologist had been informed about the presence of HPV E6/E7 mRNA. The other transplant patient had a normal Pap smear and innocuous colposcopy finding, but nevertheless qualified for cervical biopsy and canal curettage. Histological examination revealed no pathological lesions in collected tissue samples.
Similarly, HPV E6/E7 mRNA-positive females from the control group underwent additional examinations. Repeated Pap smear results revealed HSIL. Colposcopy and subsequent biopsies led to the diagnosis of CIN3 in tissues obtained during cervical canal curettage. This patient was offered LEEP and histological examination confirmed that CIN3 in the cervical canal had been excised with negative margins.
There are relatively few publications dealing with HR-HPV infection in populations of transplant recipients. The incidence of HR-HPV infection as well as abnormal Pap smear results is reported to be quite high in recipients, reaching 59% according to some studies [14–16]). However, other data suggest a low prevalence of HPV infections in kidney graft recipients, similar to that of the general population . In our study the prevalence of HR-HPV infections in both groups was similar, with the prevalence in immunocompromised women tending to be slightly lower than that in healthy controls (18,6% vs 25%, p = ns). A recently published Italian study by Origoni et al suggested that transplant recipients receiving long-term immunosuppression may not be more at risk of HPV infection and CIN than healthy controls , which is in agreement with our results. However, the mean recipient age in the above mentioned Italian study approached 38 years, and in our study 37 years, whereas it is well established that younger women are especially prone to HPV infection . Morrison et al suggested that HR-HPV infection was relatively rarely encountered among older renal graft recipients with normal Pap smear results. This applied in particular to monogamous or sexually inactive patients. Therefore it was recommended that education about avoiding high-risk sexual relations should be of prime importance among kidney graft recipients . Our results support the above mentioned recommendation. During the analysis of the correlation between HR-HPV infection and the number of lifetime sexual partners, it was noted that the incidence of HPV was slightly higher among patients from both groups that had had more than one sexual partner in their lifetime; the difference was however statistically insignificant. The kidney recipients also had a significantly higher incidence of having had only one lifetime sexual partner, which may explain the relatively low incidence of cervical HPV infection in our cohort.
Testing for E6/E7 mRNA offers a novel approach in cervical screening. There are published reports pointing out that the introduction of E6/E7 HPV mRNA testing may improve the diagnostic accuracy in HR-HPV-positive women . Benevolo et al observed that, in a group of 408 HR-HPV-positive patients with normal Pap smears (regarded as ≤ HSIL), positive HPV mRNA results were significantly more often associated with CIN ≥ 2 than with CIN ≤ 2 lesions. Therefore the authors concluded that testing for E6/E7 HPV mRNA may have a diagnostic and potentially prognostic role in the management of HR-HPV(+), HSIL(−) patients .
There is strong evidence that testing for HPV E6/E7 mRNA is more specific than testing for HPV DNA, but the sensitivity of the test may be unsatisfactory for clinical purposes. Benevolo et al conducted another study on a group of 1201 participants and concluded that E6/E7 mRNA testing was more efficient than cytology for the triage of HPV DNA-positive women. However, the sensitivity for CIN2+ was relatively low (83% in cases of ASCUS, LSIL 62% and HSIL 67%). That fact means that HPV DNA-positive women, in spite of the negative E6/E7 mRNA test result, would nevertheless require strict follow-up . In our study all the HR-HPV-positive patients, except for three females with transforming infections confirmed by means of the E6/E7 mRNA test, cleared the cervical infection within 24 months of follow-up.
Norwegian authors  have raised the issue of specificity of the test, around 30% of their patients having a positive HPV E6/E7 mRNA test result with no lesions being detected by subsequent cervical biopsy. The positive predictive value of HPV E6/E7 mRNA testing in HR-HPV-positive women with minor cervical lesions seen on cytological examination reached 70%. In our study, one of the three HPV E6/E7 mRNA-positive patients—a kidney recipient—had no abnormal tissues detectable in specimens collected during colposcopic-guided cervical biopsy and canal curettage. The explanation proposed by the Norwegian authors is based on the fact that colposcopic biopsy may miss as much as 26-42% of the CIN2+ lesions. Infections with HPV type 18 or 45 with typical localization inside the cervical canal may especially be missed on colposcopy. In fact, the Norwegian authors suggest that the 30% of the mRNA-positive patients with a negative histological confirmation of cervical disease may represent false negative results. Our patient was not scheduled for conization but remains under strict clinical follow-up and will be scheduled for repeat colposcopy and biopsy in 6 months’ time.
The clinical value of HPV E6/E7 mRNA testing as well as its future position in cervical screening algorithms remains to be established. The possibility of confirming a transforming HPV infection, thereby facilitating the early identification of women at greatest risk of cervical neoplasm development, seems very promising. This applies especially to immunocompromised renal graft recipients, that in the past were often regarded as a high risk group, although the currently published data are inconsistent. Origoni et al found no increase of CIN in population of Italian female renal graft recipients that remained under long-term follow-up . On the other hand a recently published report by Meeuwis et al analyzing data from over 1000 female kidney graft recipients confirmed the fivefold increase of risk of cervical cancer in comparison to the general population and emphasized the importance of cervical screening . According to our data, female kidney graft recipients of reproductive age are as exposed to HR-HPV infection as are healthy individuals, which may be regarded as novelty. Our results, despite the small number of HR-HPV-positive females that underwent follow-up, highlight the utility of HPV E6/E7 mRNA detection in those cases where lesions develop in the cervical canal, which often go undetected by exfoliative cytology. Timely detection of cervical dysplasia at the early stages would allow for timely and adequate therapy among these patients. The decrease of cervical cancer morbidity may be achieved in future by means of HPV vaccination, but at present there are insufficient data regarding the efficacy and safety of the available vaccines in populations of iatrogenically immunocompromised females.
Characteristic of the study and control groups
Characteristic of patients
Study group (n = 60)
Control group (n = 60)
37,3 ± 7
36,4 ± 7,1
23,63 ± 2,43
23,30 ± 3,85
0,8 ± 0,988
1,08 ± 0,979
Number of partners
P = 0.01
Study inclusion and exclusion criteria
Inclusion criteria of patients
Age 28–48 years
Trichomonas vaginalis infection
regular menstrual cycles
sexual intercourse during previous 4 days
antibiotic therapy during past 2 weeks
normal Pap smear obtained within previous 12 months
absence of symptoms of genital infection
pregnancy and puerperium
active malignant disease
fever in the previous 4 days
lack of informed consent
The cervical swabs were analyzed using the Amplicor HPV Roche Molecular Systems test designed to detect the DNA of thirteen high risk HPV types: 16, 18, 31, 33, 39, 45, 51, 52, 56, 58, 59 and 68. All the participants gave informed consent for enrollment in the study which had been approved by the Bioethical Committee of the Medical University of Warsaw.
After the initial cervical screening described above, a cohort consisting of 15 healthy women and 11 renal transplant recipients showed the presence of HR-HPV DNA in their cervical samples. As follow-up, these patients underwent further investigations. Prompt cervical smears according to the Bethesda/Papanicolau system, as well as colposcopy, were performed in order to plan further treatment if necessary.
The HR-HPV DNA-positive females remained under close observation and cervical swabs were obtained again after 24 months. These were analyzed for the presence of HR-HPV E6/E7 mRNA using the CE-IVD- certified Nucli-Sense EasyQ test (Biomerieux, France), which detected the mRNA of HR-HPV types 16, 18, 31, 33 and 45. All the patients with positive HR-HPV E6/E7 mRNA test results were subjected to further investigations.
All the samples obtained from HPV DNA-positive females after 24 months of follow-up were also analyzed using the CE-IVD-certified Linear Array Genotyping Test (Roche, Switzerland) which detected of DNA of 37 HPV types (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84, IS39 and CP6108). This was done in order to exclude the possibility that these females were carrying other persistent cervical HPV infections.
Atypical squamous cells of undetermined significance
Body mass index
CE mark for in vitro diagnostic devices indicating fulfillment of the applicable European Directive
Cervical intraepithelial neoplasia
Minor cervical intraepithelial neoplasia
Medium cervical intraepithelial neoplasia
Severe cervical intraepithelial neoplasia
CIN2 and 3
High risk human papillomavirus
High grade squamous intraepithelial lesion
Loop electrosurgical excision procedure
Low grade squamous intraepithelial lesion.
The study was supported financially by the Medical University of Warsaw, Poland.
- Wong G, Chapman JR, Craig JC: Cancer screening in renal transplant recipients: what is the evidence? Clin J Am Soc Nephrol 2008,3(Suppl 2):S87-S100.PubMedPubMed CentralView Article
- Patel HS, Silver AR, Northover JM: Anal cancer in renal transplant patients. Int J Colorectal Dis 2007,22(1):1-5.PubMedView Article
- Arends MJ, Benton EC, McLaren KM, Stark LA, Hunter JA, Bird CC: Renal allograft recipients with high susceptibility to cutaneous malignancy have an increased prevalence of human papillomavirus DNA in skin tumours and a greater risk of anogenital malignancy. Br J Cancer 1997,75(5):722-728. 10.1038/bjc.1997.128PubMedPubMed CentralView Article
- Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM, Gaston RS, Roth D, Scandling JD, Singer GG: Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000,11(Suppl 15):S1-S86.PubMed
- Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, Chapman JR, Webster AC, Kaldor JM, Grulich AE: Cancer incidence before and after kidney transplantation. JAMA 2006,296(23):2823-2831. 10.1001/jama.296.23.2823PubMedView Article
- Fairley CK, Sheil AG, McNeil JJ, Ugoni AM, Disney AP, Giles GG, Amiss N: The risk of ano-genital malignancies in dialysis and transplant patients. Clin Nephrol 1994,41(2):101-105.PubMed
- Meeuwis KA, van Rossum MM, van de Kerkhof PC, Hoitsma AJ, Massuger LF, de Hullu JA: Skin cancer and (pre)malignancies of the female genital tract in renal transplant recipients. Transpl Int 2010,23(2):191-199. 10.1111/j.1432-2277.2009.00975.xPubMedView Article
- Palefsky JM, Holly EA: Chapter 6: immunosuppression and co-infection with HIV. J Natl Cancer Inst Monogr 2003, 31: 41-46.PubMedView Article
- Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlée F, Franco EL: Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007,357(16):1579-1588. 10.1056/NEJMoa071430PubMedView Article
- Reuschenbach M, Clad A, von Knebel Doeberitz C, Wentzensen N, Rahmsdorf J, Schaffrath F, Griesser H, Freudenberg N, von Knebel Doeberitz M: Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results. Gynecol Oncol 2010,119(1):98-105. 10.1016/j.ygyno.2010.06.011PubMedView Article
- zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002,2(5):342-350. 10.1038/nrc798PubMedView Article
- Martin CM, O’Leary JJ: Histology of cervical intraepithelial neoplasia and the role of biomarkers. Best Pract Res Clin Obstet Gynaecol 2011,25(5):605-615. 10.1016/j.bpobgyn.2011.04.005PubMedView Article
- Brink AA, Snijders PJ, Meijer CJ, Berkhof J, Verheijen RH: HPV testing in cervical screening. Best Pract Res Clin Obstet Gynaecol 2006,20(2):253-266. 10.1016/j.bpobgyn.2005.10.009PubMedView Article
- Veroux M, Corona D, Scalia G, Garozzo V, Gagliano M, Giuffrida G, Costanzo CM, Giaquinta A, Palermo I, Zappalà D, Tallarita T, Zerbo D, Russo R, Cappellani A, Franchina C, Scriffignano V, Veroux P, et al.: Surveillance of human papilloma virus infection and cervical cancer in kidney transplant recipients: preliminary data. Transplant Proc 2009,41(4):1191-1194. 10.1016/j.transproceed.2009.03.015PubMedView Article
- Seshadri L, George SS, Vasudevan B, Krishna S: Cervical intraepithelial neoplasia and human papilloma virus infection in renal transplant recipients. Indian J Cancer 2001,38(2–4):92-95.PubMed
- Fairley CK, Chen S, Tabrizi SN, McNeil J, Becker G, Walker R, Atkins RC, Thomson N, Allan P, Woodburn C, et al.: Prevalence of HPV DNA in cervical specimens in women with renal transplants: a comparison with dialysis-dependent patients and patients with renal impairment. Nephrol Dial Transplant 1994,9(4):416-420.PubMed
- Morrison EA, Dole P, Sun XW, Stern L, Wright TC Jr: Low prevalence of human papillomavirus infection of the cervix in renal transplant recipients. Nephrol Dial Transplant 1996,11(8):1603-1606. 10.1093/oxfordjournals.ndt.a027621PubMedView Article
- Origoni M, Stefani C, Dell’Antonio G, Carminati G, Parma M, Candiani M: Cervical Human Papillomavirus in transplanted Italian women: a long-term prospective follow-up study. J Clin Virol 2011,51(4):250-254. 10.1016/j.jcv.2011.05.017PubMedView Article
- de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX: Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007,7(7):453-459. 10.1016/S1473-3099(07)70158-5PubMedView Article
- Bertuccio MP, Spataro P, Caruso C, Picerno I: Detection of human papillomavirus E6/E7 mRNA in women with high-risk HPV types 16, 18, 31, 33 and 45 which are associated with the development of human cervical cancer. Eur J Gynaecol Oncol 2011,32(1):62-64.PubMed
- Benevolo M, Terrenato I, Mottolese M, Marandino F, Carosi M, Rollo F, Ronchetti L, Muti P, Mariani L, Sindico S, Vocaturo G, Vocaturo A: Diagnostic and prognostic validity of the human papillomavirus E6/E7 mRNA test in cervical cytological samples of HC2-positive patients. Cancer Causes Control 2011,22(6):869-875. 10.1007/s10552-011-9757-0PubMedView Article
- Benevolo M, Vocaturo A, Caraceni D, French D, Rosini S, Zappacosta R, Terrenato I, Ciccocioppo L, Frega A, Giorgi Rossi P: Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test. J Clin Microbiol 2011,49(7):2643-2650. 10.1128/JCM.02570-10PubMedPubMed CentralView Article
- Sørbye SW, Fismen S, Gutteberg T, Mortensen ES: Triage of women with minor cervical lesions: data suggesting a “test and treat” approach for HPV E6/E7 mRNA testing. PLoS One 2010,5(9):e12724. 10.1371/journal.pone.0012724PubMedPubMed CentralView Article
- Meeuwis KA, Melchers WJ, Bouten H, van de Kerkhof PC, Hinten F, Quint WG, Massuger LF, Hoitsma AJ, van Rossum MM, de Hullu JA: Anogenital Malignancies in Women After Renal Transplantation Over 40 Years in a Single Center. Transplantation in press
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.